AstraZeneca PLC on Wednesday announced it will provide new safety and efficacy data on several of its cancer drugs, purporting to show longer survival for cancer patients.

Between September 9 and September 13, the Cambridge-based pharmaceutical firm will present data at the European Society for Medical Oncology Congress 2022 in Paris.

AstraZeneca will present data for cancer drugs Imfinzi, Tagrisso, Lynparza and Enhertu, the latter of which is developed with its Tokyo-based partner Daiichi Sankyo Co Ltd.

All cancer drugs that will be highlighted have been approved for some form of cancer treatments in the US, EU and other countries.

‘New evidence will demonstrate how our medicines are prolonging patient survival across several cancers,’ said Dave Fredrickson, executive vice president of AstraZeneca’s Oncology Business Unit.

Astra will share seven-year overall survival data on Lynparza in a form of advanced ovarian cancer. ‘This is the longest follow-up for any PARP inhibitor in newly diagnosed advanced ovarian cancer,’ the firm explained.

PARP stands for poly adenosine diphosphate-ribose polymerase, an enzyme type that helps repair DNA damage in cells. They also help repair cancer cells. Inhibitors can prevent that reparation.

Further, AstraZeneca will provide data on MEDI5752, an antibody that targets the proteins PD-1 and CTLA-4 in lung cancer. Both proteins keep T cells from killing other cells, including cancer cells.

Copyright 2022 Alliance News Limited. All Rights Reserved.